Machine learning (ML) methods enable computers to address problems by learning from existing data. Such applications are becoming commonplace in molecular sciences. Interest in applying ML techniques across chemical compound space, from predicting properties to designing molecules and materials is in the surge. Especially, ML models have started to accelerate computational chemistry, and are often as accurate as state‐of‐the‐art electronic/atomistic models. Being an integral part of the ML architecture, representation of a molecular entity, uniquely encoded, plays a crucial role to what extent an ML model would be accurately predicting the desired property. This review aims to demonstrate a hierarchy of representations which has been introduced, to capture all degrees of freedom of a molecule or an atom the best, to map the quantum mechanical properties. We discuss their diverse applications how they have been instrumental in harnessing the growing field of ML accelerated computational modeling.

The coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, is an acute respiratory disease that has been classified as a pandemic by the World Health Organization (WHO). The sudden spike in the number of infections and high mortality rates have put immense pressure on the public healthcare systems. Hence, it is crucial to identify the key factors for mortality prediction to optimize patient treatment strategy. Different routine blood test results are widely available compared to other forms of data like X-rays, CT-scans, and ultrasounds for mortality prediction. This study proposes machine learning (ML) methods based on blood tests data to predict COVID-19 mortality risk. A powerful combination of five features: neutrophils, lymphocytes, lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (hs-CRP), and age helps to predict mortality with 96% accuracy. Various ML models (neural networks, logistic regression, XGBoost, random forests, SVM, and decision trees) have been trained and performance compared to determine the model that achieves consistently high accuracy across the days that span the disease. The best performing method using XGBoost feature importance and neural network classification, predicts with an accuracy of 90% as early as 16 days before the outcome. Robust testing with three cases based on days to outcome confirms the strong predictive performance and practicality of the proposed model. A detailed analysis and identification of trends was performed using these key biomarkers to provide useful insights for intuitive application. This study provide solutions that would help accelerate the decision-making process in healthcare systems for focused medical treatments in an accurate, early, and reliable manner.